Sun Yat-sen University

This study tests whether giving a combination of four drugs before surgery can shrink stage III lung cancer that was previously too large or spread to be removed. About 36 adults with this type of lung cancer will receive the drug combo, then doctors will check if the tumor has s…

This study looks at whether people with advanced head and neck cancer who had a good response to chemo-immunotherapy before surgery can safely get less radiation after neck lymph node removal. The goal is to keep cancer from coming back while improving quality of life. About 50 p…

This study tests an experimental drug called QL1706 in 45 adults with advanced bone or soft tissue sarcoma that cannot be removed by surgery. Participants receive the drug every 3 weeks. The main goal is to see if the drug can stop tumor growth for at least 12 weeks, while also c…

This study tests a new way of giving chemotherapy called adaptive therapy for people with advanced breast cancer that has gotten worse after standard treatments. The goal is to see if this approach can delay the cancer from growing again. About 192 adults will take part in this p…

This study tests whether giving chemotherapy directly into the liver plus an immunotherapy drug (tislelizumab) before surgery, followed by more immunotherapy after surgery, can prevent liver cancer from returning in high-risk patients. About 39 adults with liver cancer that is be…

This study tests a combination of three drugs (chidamide, sintilimab, and bevacizumab) in 34 people with advanced extrapulmonary neuroendocrine carcinoma that has worsened after standard first-line therapy. The goal is to see if this treatment can shrink tumors or slow disease pr…

This study tests whether giving the immunotherapy drug adebrelimab directly into the liver artery works better than standard IV infusion, when combined with chemotherapy and another targeted drug (bevacizumab). About 76 adults with advanced liver cancer that has spread will be ra…

This study tests two ways to treat lung cancer that has spread to the brain. One group gets focused radiation plus a drug called bevacizumab. The other gets whole-brain radiation that tries to protect the memory center. The goal is to see which approach better controls tumors and…

This study tests whether giving radiation only when needed (salvage) is as effective as giving it right away after immunotherapy and chemotherapy in people with nasopharyngeal cancer that has spread. About 260 adults aged 18-70 with untreated, metastatic disease will be randomly …

This study tests whether adding two targeted drugs (cetuximab and envafolimab) to a strong chemotherapy cocktail works better than the standard treatment for people with a specific type of advanced colorectal cancer that has spread to the left side of the body. About 198 adults w…

This study is for people with stage IB-IIIA non-small cell lung cancer who have had surgery to remove the tumor. Researchers want to see if a blood test that detects tiny bits of cancer DNA (called ctDNA-MRD) can help decide who needs extra immunotherapy (toripalimab) and who can…

This study compares a reduced dose of radiation to the standard dose for low-risk areas in people with nasopharyngeal cancer. The goal is to see if the lower dose can control the cancer just as well while causing fewer side effects and improving quality of life. About 700 adults …

This phase 3 trial tests whether adding two drugs—toripalimab (an immunotherapy) and capecitabine (a chemotherapy pill)—after standard chemoradiation can help prevent esophageal cancer from coming back. About 242 adults with advanced esophageal cancer that hasn't spread after ini…

This study tests a new way to deliver radiation for early-stage lung cancer or small lung tumors that have spread from other cancers. Instead of adding a safety margin around the tumor, doctors will use real-time imaging to target only the tumor itself. The goal is to see if this…

This study tests whether adding precise, high-dose radiation (SBRT) to standard drug therapy (targeted agents and immunotherapy) can help people with kidney cancer that has spread to 5 or fewer spots live longer without the cancer growing. About 252 adults with kidney cancer will…

This early-phase study tests a new treatment called IX001 TCR-T for people with advanced pancreatic cancer that has a specific genetic change (KRAS G12V). The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack the cancer. The…

This study tests a drug called toripalimab, which helps the immune system fight cancer. It is for people with advanced solid tumors that have specific gene changes (POLE or POLD1 mutations) but not high microsatellite instability. About 35 adults who have not responded to standar…

This study tests whether adding the immunotherapy drug Toripalimab to different platinum-based chemotherapy regimens, followed by standard chemoradiation, can help people with advanced nasopharyngeal cancer live longer without the disease getting worse. About 243 adults aged 18-7…

This study tests two new drug combinations for people with peripheral T-cell lymphoma (a rare blood cancer) that has returned or not improved after standard treatment. About 101 participants will receive either golidocitinib plus mitoxantrone liposome or golidocitinib plus chidam…

This study tests whether a combination of two drugs (orelabrutinib and rituximab) followed by long-term orelabrutinib can control follicular lymphoma that has returned or stopped responding to prior therapy. About 32 adults with certain types of follicular lymphoma will receive t…

This study tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (lenvatinib) before surgery can shrink kidney tumors enough to allow partial kidney removal in patients who otherwise would need full kidney removal. Ab…

This study tests whether adding an immunotherapy drug (pucotenlimab) to standard chemotherapy (CAPOX) helps shrink tumors more effectively in people with locally advanced rectal cancer. About 556 adults aged 18-75 will be randomly assigned to receive either the drug combo or chem…

This study tests whether adding low-dose radiation and an immunotherapy drug (cadonilimab) to standard chemotherapy can better control advanced nasopharyngeal cancer. About 380 adults with newly diagnosed, advanced-stage disease will be randomly assigned to receive either the new…

This study tests whether early, specialized heart monitoring and care can help people with advanced lung cancer live longer and have fewer heart-related side effects while receiving standard cancer treatments like radiation, chemotherapy, and immunotherapy. About 524 adults with …

This study is testing a new way to figure out where a cancer started when doctors can't find the original tumor. Researchers will use a computer model to analyze DNA patterns from 120 cancer patients. The goal is to help guide more precise treatment for these hard-to-diagnose can…

This study tests whether adding Houyanqing Oral Liquid to standard care can prevent severe mouth sores caused by radiation therapy in people with nasopharyngeal cancer. About 244 adults aged 18–75 who need radiation will be randomly assigned to receive either the herbal liquid pl…

This study tests whether Xinlikang capsules can reduce severe tiredness and help the immune system recover in people with diffuse large B-cell lymphoma who finished chemotherapy and are in remission. About 80 adults will receive either the capsule or a placebo for a set time. The…

This study is looking at whether a simple blood test can find tiny bits of tumor DNA (called ctDNA) in children with neuroblastoma. The goal is to see if this test can help doctors know how well treatment is working and spot the cancer coming back earlier than usual scans. About …

This study follows 2000 adults with moderate or severe mitral regurgitation (a leaky heart valve) to identify factors that raise the risk of death or heart failure. Researchers will use this information to create a risk model that helps doctors decide on the best treatment. Parti…